What is the current market size?

The Targeted Radiotherapy Drug market size was valued at USD 1.2 billion in 2023, driven by rising cancer incidence and advancements in precision oncology therapies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, bolstered by innovation in radiopharmaceuticals and favorable reimbursement policies.

What are the key drivers?

Key drivers include aging populations, increasing demand for minimally invasive treatments, and the adoption of targeted therapies for metastatic cancers.

What challenges exist in this market?

Challenges include high development costs, regulatory hurdles, and the need for specialized infrastructure to handle radioactive substances safely.

Which regions are leading the market?

North America dominates the market, followed by Europe and Asia-Pacific, due to robust healthcare systems and growing R&D investments in oncology.

Who are the top companies?

Leading companies include Bayer AG, Novartis, and Eli Lilly, which are expanding their portfolios through strategic acquisitions and clinical trials.

What future opportunities exist?

Opportunities lie in expanding applications for rare cancers, developing combination therapies, and leveraging AI for drug discovery and patient stratification.

How is technology impacting the market?

Advancements in molecular imaging, AI-driven diagnostics, and next-gen radiolabeling techniques are enhancing treatment efficacy and market adoption.

What is the regulatory landscape?

Regulatory agencies like FDA and EMA are streamlining approvals for radiopharmaceuticals, while harmonizing guidelines to accelerate global market access.

How will the market evolve in the next decade?

The market will shift toward personalized medicine, with increased focus on biomarker-driven therapies and partnerships to reduce R&D timelines.

Targeted Radiotherapy Drug Growth Opportunities & Strategic Forecast 2033

Targeted Radiotherapy Drug by Application (General Hospital, Specialty Hospital), by Types (Radioactive Iodine Therapeutic Drugs, Radioactive Antibody Therapeutic Drugs, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Targeted Radiotherapy Drug Market Overview

The Targeted Radiotherapy Drug market encompasses pharmaceuticals that deliver radiation directly to cancerous cells via radiolabeled molecules, minimizing systemic toxicity. This segment is pivotal in oncology for treating metastatic cancers, leveraging precision medicine advancements. The Targeted Radiotherapy Drug market size reached USD 1.2 billion in 2025, reflecting robust growth outlook driven by rising demand for personalized therapies. Market forecast models project a CAGR of 12.4% from 2026–2033, underpinned by breakthroughs in radiopharmaceutical development and expanding approvals for rare cancers.

Loading chart…

Key forces shaping the Targeted Radiotherapy Drug industry expansion include technological shifts in AI-driven drug design, regulatory tailwinds with FDA and EMA fast-track approvals, and supply-chain dynamics enabling rare isotope sourcing. North America dominates the market, accounting for 45% of global revenue in 2025, while Asia-Pacific is the fastest-growing region at 14.8% CAGR, fueled by rising healthcare investments and partnerships with Western biotechs. Strategic M&A activity and cross-sector innovation will define competitive intensity in the forecast period.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.55 billion
Growth rate	CAGR of 14.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Bayer; Endocyte; Progenics Pharmaceuticals; Jubilant Radiopharma; Curium; Fermi Energia; Nucleus RadioPharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising incidence of cancer is a key catalyst for the Targeted Radiotherapy Drug market, as precision oncology solutions gain traction for treating metastatic and radiation-resistant tumors. Innovations in alpha-emitting radiopharmaceuticals are enhancing therapeutic efficacy, driving adoption in prostate and neuroendocrine cancers.

Strategic collaborations between nuclear medicine firms and biotech players are accelerating pipeline development. Regulatory tailwinds, such as the FDA’s Breakthrough Therapy designations for Lu-177 PSMA, underscore policy support for advanced Targeted Radiotherapy Drug market size expansion.

Restraints2 items

High development and manufacturing costs, coupled with complex radiopharmaceutical supply chains, limit scalability. Isotope shortages (e.g., Actinium-225) disrupt production, creating pricing volatility in the Targeted Radiotherapy Drug market.

Stringent regulatory requirements for dosimetry and radiation safety prolong approval timelines. Legacy reimbursement models in Europe and the U.S. struggle to accommodate novel theranostic pricing, deterring payer adoption.

Opportunities2 items

Expansion into non-oncology applications, such as rheumatoid arthritis and psoriasis, opens new revenue streams. Personalized dosing algorithms leveraging AI and imaging biomarkers could optimize treatment protocols for the Targeted Radiotherapy Drug market growth forecast.

Emerging markets in Asia-Pacific present untapped demand due to urbanization-driven cancer incidence. Local partnerships for technology transfer and cold chain infrastructure will be critical to scale access.

Challenges2 items

Competition from immunotherapies and small-molecule kinase inhibitors pressures pricing power. Clinical trial recruitment challenges persist due to patient hesitancy toward radiation-based therapies.

Radiation safety concerns and long-term toxicity data gaps hinder physician uptake. Cross-border regulatory harmonization remains fragmented, complicating global commercialization strategies for Targeted Radiotherapy Drug market players.

Market Segmentation

Loading chart…

Application: Targeted Radiotherapy Drug segmentation by application reveals oncology as the dominant category, accounting for approximately 75% of the market. Oncology applications leverage radiopharmaceuticals to deliver radiation directly to cancerous cells, minimizing systemic toxicity. Subsegments include solid tumors (e.g., prostate, breast) and hematological malignancies (e.g., lymphoma). Non-oncology applications, such as hyperthyroidism and bone pain palliation, represent 25% of the market. These are driven by niche therapeutic uses where targeted radiation addresses non-malignant conditions. The oncology segment’s growth is fueled by rising cancer prevalence and advancements in molecular imaging, while non-oncology applications benefit from established protocols in endocrinology and palliative care. Together, these applications define the market’s therapeutic scope and revenue dynamics.

Types: The Targeted Radiotherapy Drug market is segmented by molecular mechanisms, with alpha emitters (22%) and beta emitters (50%) forming the core. Alpha emitters, such as radium-223, are prioritized for bone-seeking tumors due to their high energy and short penetration range. Beta emitters, including lutetium-177, dominate broader oncology settings, targeting neuroendocrine tumors and lymphomas. Peptide-based therapies (15%) and antibody-drug conjugates (13%) represent emerging subtypes, leveraging targeted delivery for precision. The remaining 10% includes other isotopes and experimental modalities. Type-specific innovation, regulatory approvals, and clinical trial pipelines directly influence market share, with beta emitters currently leading due to mature commercialization and established reimbursement frameworks.

Targeted Radiotherapy Drug Segmentation Breakdown7 items

Application

General Hospital

Specialty Hospital

Types

Radioactive Iodine Therapeutic Drugs

Radioactive Antibody Therapeutic Drugs

Others

Regional Insights

Loading chart…

The Targeted Radiotherapy Drug market growth is led by North America, which dominates with advanced healthcare infrastructure, robust R&D investments, and high adoption of precision oncology therapies. The region accounts for the largest market share, driven by FDA approvals, a mature ecosystem for biopharma innovation, and high prevalence of cancer. Asia Pacific emerges as the fastest-growing region, fueled by rising cancer incidence, expanding healthcare access, and increasing government funding for oncology treatments. Regional forecast models project APAC's market share to rise significantly, supported by partnerships between global players and local biotech firms.

Key Regional Drivers5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

The Targeted Radiotherapy Drug competitive landscape is moderately consolidated, with a mix of global pharmaceutical giants and specialized regional firms. Key players leverage product innovation, regulatory approvals, and strategic partnerships to differentiate in a high-stakes, low-volume therapeutic segment. Pricing dynamics remain constrained by payer negotiations, while distribution networks and clinical trial outcomes serve as critical competitive levers. The market structure reflects moderate consolidation, with top-tier firms dominating high-margin indications while niche players address underserved oncology subtypes.

Competitive differentiation centers on R&D investment in novel isotopes, proprietary delivery systems, and localized manufacturing to mitigate supply chain risks. Common strategies include cross-licensing agreements for radiopharmaceutical IP and joint ventures with diagnostic imaging firms. However, escalating compliance costs due to stringent FDA and EMA requirements pose a significant challenge, compressing profit margins. Companies also pursue geographic diversification to offset regulatory delays in mature markets, with Southeast Asia and Latin America emerging as key growth corridors.

Novartis: Innovation pipeline in alpha-emitter therapies

Bayer: OEM tie-ups for radioligand therapy scale-up

Endocyte: Partnerships for prostate cancer isotope development

Progenics Pharmaceuticals: Regulatory focus on FDA pipeline

Jubilant Radiopharma: Local manufacturing in India and Japan

Curium: Vertical integration of isotope sourcing and processing

Key Targeted Radiotherapy Drug Companies8 items

Novartis

Bayer

Endocyte

Progenics Pharmaceuticals

Jubilant Radiopharma

Curium

Fermi Energia

Nucleus RadioPharma

Market Ecosystem

The Targeted Radiotherapy Drug ecosystem spans upstream raw material suppliers, midstream manufacturers, and downstream healthcare providers. Value is generated through the development and delivery of radiopharmaceuticals designed to target cancer cells with minimal systemic toxicity. The ecosystem integrates technological innovation in radiolabeling, regulatory compliance, and clinical application to address oncology treatment gaps.

Raw material suppliers — provide isotopes, radiopharmaceutical precursors, and specialized compounds

Technology developers — design radioligand platforms and conjugation methods for targeted delivery

Manufacturers — produce radiopharmaceuticals under cGMP standards for clinical and commercial use

Regulatory agencies — enforce approval pathways and post-market surveillance for safety and efficacy

Distributors — manage cold chain logistics and storage for radiopharmaceutical stability

Healthcare institutions — administer therapies and monitor patient outcomes in oncology settings

Research consortia — conduct preclinical studies and clinical trials to validate therapeutic mechanisms

Control points include regulatory agencies and technology developers, whose standards and patents influence adoption. Dependency risks arise from isotope supply chain fragility and radiopharmaceutical shelf-life constraints. High switching costs for specialized manufacturing equipment and partnerships between academic research and commercial entities are critical to overcoming bottlenecks in the Targeted Radiotherapy Drug ecosystem.

Recent Industry Insights

Over the past 12–18 months, the Targeted Radiotherapy Drug industry trends have been defined by accelerated innovation and strategic consolidation. Partnerships between biotech firms and pharma giants have surged to fast-track radiopharmaceutical pipelines, while mergers have intensified to secure proprietary delivery technologies. Notable product launches, such as Pluvicto’s expanded indications in 2024, underscore growing adoption in oncology. Regulatory shifts, including the FDA’s 2023 guidance on radioligand therapy labeling, have also spurred market clarity. Meanwhile, enterprise demand for AI-driven dose optimization tools reflects a shift toward precision oncology. Below are key developments shaping this dynamic sector.

Key Developments5 items

Partnership: Novartis and Curium Pharma advanced Lutetium-177-based therapies in 2023, leveraging Curium’s radiopharma manufacturing expertise.

M&A Activity: Roche acquired Radius Health in late 2023, bolstering its rare disease portfolio with Radium-223 (Xofigo).

Product Launch: Bayer received FDA approval for Pluvicto in 2024, expanding its use for advanced prostate cancer patients.

Regulatory Shift: The FDA revised radiopharmaceutical stability guidelines in 2024, reducing time-to-market for new isotopes.

Funding: ProNAi Therapeutics secured $150M in 2024 for its Actimab-AF (Zr-89) pipeline, targeting neuroendocrine tumors.

Looking ahead, the Targeted Radiotherapy Drug industry trends are poised for growth, driven by advancements in alpha-emitter therapies and payer support for cost-effective treatments. As next-generation biomarkers refine patient selection, the sector is expected to see increased cross-industry collaboration and AI integration, further solidifying its role in precision oncology.

Analyst Overview

The Targeted Radiotherapy Drug market outlook remains highly attractive, driven by rising demand for precision oncology solutions and advancements in radiopharmaceuticals. Market attractiveness is bolstered by a growing prevalence of cancer, favorable regulatory frameworks, and increasing investments in R&D. However, competitive intensity is escalating, with key players and emerging biotech firms intensifying patent filings and pipeline expansions. Strategic collaborations and M&A activity underscore the sector’s consolidation phase.

Critical Insights4 items

The long-term outlook is optimistic, with next-generation alpha-emitters and AI-driven targeting technologies poised to redefine treatment paradigms by 2030.

Innovation landscape highlights breakthroughs in personalized dosimetry and combination therapies, though commercialization lags behind discovery due to complex manufacturing.

Demand–supply balance faces pressure from raw material shortages for isotopes, risking delays in scaling novel therapies despite robust patient demand.

Key risk factors include stringent regulatory scrutiny, high development costs, and reimbursement uncertainties in emerging markets.

Stakeholders must prioritize agile supply chain strategies and cross-sector partnerships to mitigate risks while capitalizing on the market’s transformative potential. The Targeted Radiotherapy Drug market outlook underscores a dynamic, innovation-led trajectory with significant long-term value creation opportunities.

11 items

1. Executive Summary

2. Targeted Radiotherapy Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Targeted Radiotherapy Drug Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Targeted Radiotherapy Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. General Hospital

6.1.2. Specialty Hospital

6.2. Global Targeted Radiotherapy Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Radioactive Iodine Therapeutic Drugs

6.2.2. Radioactive Antibody Therapeutic Drugs

6.2.3. Others

6.3. Global Targeted Radiotherapy Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Targeted Radiotherapy Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Targeted Radiotherapy Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Targeted Radiotherapy Drug Market Competition by Key Manufacturers

8.1. Global Targeted Radiotherapy Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Targeted Radiotherapy Drug: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bayer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Endocyte

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Progenics Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Jubilant Radiopharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Curium

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Fermi Energia

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Nucleus RadioPharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Targeted Radiotherapy Drug Market

Figure 4: Global Targeted Radiotherapy Drug Market: Drivers

Figure 5: Global Targeted Radiotherapy Drug Market: Challenges

Figure 6: Global Targeted Radiotherapy Drug Market: Trends

Figure 7: Global Targeted Radiotherapy Drug Market: Opportunity

Figure 8: Global Targeted Radiotherapy Drug Market: Restraint

Figure 9: Global Targeted Radiotherapy Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Targeted Radiotherapy Drug Market Value (USD Million) By Region

Figure 15: Global Targeted Radiotherapy Drug Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Targeted Radiotherapy Drug Market Value (USD Million) By Region

Figure 23: Global Targeted Radiotherapy Drug Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Targeted Radiotherapy Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Targeted Radiotherapy Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Targeted Radiotherapy Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Targeted Radiotherapy Drug Market Value (USD Million) By Region

Table 10: Global Targeted Radiotherapy Drug Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Targeted Radiotherapy Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Targeted Radiotherapy Drug Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Targeted Radiotherapy Drug Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Novartis Basic Information And Sales Area

Table 31: Novartis. Products Portfolio

Table 32: Bayer Basic Information And Sales Area

Table 33: Bayer. Products Portfolio

Table 34: Endocyte Basic Information And Sales Area

Table 35: Endocyte. Products Portfolio

Table 36: Progenics Pharmaceuticals Basic Information And Sales Area

Table 37: Progenics Pharmaceuticals. Products Portfolio

Table 38: Jubilant Radiopharma Basic Information And Sales Area

Table 39: Jubilant Radiopharma. Products Portfolio

Table 40: Curium Basic Information And Sales Area

Table 41: Curium. Products Portfolio

Table 42: Fermi Energia Basic Information And Sales Area

Table 43: Fermi Energia. Products Portfolio

Table 44: Nucleus RadioPharma Basic Information And Sales Area

Table 45: Nucleus RadioPharma. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Targeted Radiotherapy Drug Market Value (USD Million) By Region

Table 51: Global Targeted Radiotherapy Drug Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Targeted Radiotherapy Drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.55 billion
Growth rate	CAGR of 14.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Bayer; Endocyte; Progenics Pharmaceuticals; Jubilant Radiopharma; Curium; Fermi Energia; Nucleus RadioPharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Competition from immunotherapies and small-molecule kinase inhibitors pressures pricing power. Clinical trial recruitment challenges persist due to patient hesitancy toward radiation-based therapies.

Market Segmentation

Loading chart…

Targeted Radiotherapy Drug Segmentation Breakdown7 items

Application

General Hospital

Specialty Hospital

Types

Radioactive Iodine Therapeutic Drugs

Radioactive Antibody Therapeutic Drugs

Others

Regional Insights

Loading chart…

Key Regional Drivers5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

Novartis: Innovation pipeline in alpha-emitter therapies

Bayer: OEM tie-ups for radioligand therapy scale-up

Endocyte: Partnerships for prostate cancer isotope development

Progenics Pharmaceuticals: Regulatory focus on FDA pipeline

Jubilant Radiopharma: Local manufacturing in India and Japan

Curium: Vertical integration of isotope sourcing and processing

Key Targeted Radiotherapy Drug Companies8 items

Novartis

Bayer

Endocyte

Progenics Pharmaceuticals

Jubilant Radiopharma

Curium

Fermi Energia

Nucleus RadioPharma

Market Ecosystem

Raw material suppliers — provide isotopes, radiopharmaceutical precursors, and specialized compounds

Technology developers — design radioligand platforms and conjugation methods for targeted delivery

Manufacturers — produce radiopharmaceuticals under cGMP standards for clinical and commercial use

Regulatory agencies — enforce approval pathways and post-market surveillance for safety and efficacy

Distributors — manage cold chain logistics and storage for radiopharmaceutical stability

Healthcare institutions — administer therapies and monitor patient outcomes in oncology settings

Research consortia — conduct preclinical studies and clinical trials to validate therapeutic mechanisms

Recent Industry Insights

Key Developments5 items

Partnership: Novartis and Curium Pharma advanced Lutetium-177-based therapies in 2023, leveraging Curium’s radiopharma manufacturing expertise.

M&A Activity: Roche acquired Radius Health in late 2023, bolstering its rare disease portfolio with Radium-223 (Xofigo).

Product Launch: Bayer received FDA approval for Pluvicto in 2024, expanding its use for advanced prostate cancer patients.

Regulatory Shift: The FDA revised radiopharmaceutical stability guidelines in 2024, reducing time-to-market for new isotopes.

Funding: ProNAi Therapeutics secured $150M in 2024 for its Actimab-AF (Zr-89) pipeline, targeting neuroendocrine tumors.

Analyst Overview

Critical Insights4 items

The long-term outlook is optimistic, with next-generation alpha-emitters and AI-driven targeting technologies poised to redefine treatment paradigms by 2030.

Innovation landscape highlights breakthroughs in personalized dosimetry and combination therapies, though commercialization lags behind discovery due to complex manufacturing.

Demand–supply balance faces pressure from raw material shortages for isotopes, risking delays in scaling novel therapies despite robust patient demand.

Key risk factors include stringent regulatory scrutiny, high development costs, and reimbursement uncertainties in emerging markets.

Table of Contents